Bicara Therapeutics

Bicara Therapeutics

  • Founded: 2020
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin1b
  • Therapy area: Squamous cell carcinoma
  • Drug types: ONC
  • Lead product: BCA101
  • Product link:
  • Funding: $108M B Mar 2023; $40M seed Mar 2021
  • Investors: Red Tree Venture Capital, RA Capital Management, F-Prime Capital, Eight Roads Ventures, Invus, Piper Heartland Healthcare Capital, Premji Invest, Omega Funds, Bioqube Ventures, Acorn Bioventures, Janus Henderson Investors

job board

Short description:

Dual-Action Biologics, Antibodies

Drug notes:

Also Clin1 multiple cancers; BCA356 Clin0 solid tumors; undisclosed programs RD solid tumors

Long description:

Bicara Therapeutics is developing bifunctional antibodies for precision targeted therapies in immuno-oncology. Cancers use various mechanisms to prevent the immune system from their clearance including manipulating the tumor microenvironment. Bicara is using their platform to design bifunctional molecules that precisely target the tumor and deliver a tumor-modulating payload. Besides tumor cell recognition, the second function of the drug is to trap signaling molecules in the tumor microenvironment. By delivering a payload to the tumor, Bicara’s strategy minimizes side effects as lower doses of drug are required for the anti-tumor effect. Bicara’s lead program, BCA101, is in clinical trials for patients with squamous cell carcinoma.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy